BioCentury
ARTICLE | Company News

Oxford BioMedica cancer, gene/cell therapy, neurology news

September 8, 2008 7:00 AM UTC

At June 30, the company had £27 million ($49.8 million) in cash and a six-month operating loss of £3 million ($5.5 million). ...